If sequential NGAL testing is validated in future research as reliable for monitoring DGF resolution or timely diagnosis of early AKI, it could guide timely intervention and thereby significantly reduce costs by preventing severe complications [31, 32]. This evidence concerns the gene LCN2 and acute kidney injury.